AU2021260191A1 - Diagnostic methods using miR-485-3p expression - Google Patents

Diagnostic methods using miR-485-3p expression Download PDF

Info

Publication number
AU2021260191A1
AU2021260191A1 AU2021260191A AU2021260191A AU2021260191A1 AU 2021260191 A1 AU2021260191 A1 AU 2021260191A1 AU 2021260191 A AU2021260191 A AU 2021260191A AU 2021260191 A AU2021260191 A AU 2021260191A AU 2021260191 A1 AU2021260191 A1 AU 2021260191A1
Authority
AU
Australia
Prior art keywords
mir
nucleotides
aspects
subject
inhibitor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2021260191A
Other languages
English (en)
Inventor
Dae Hoon Kim
Yu Na Lim
Hyun Su Min
Jae Woong Min
Byung Gyu Park
Jin-Hyeob RYU
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biorchestra Co Ltd
Original Assignee
Biorchestra Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biorchestra Co Ltd filed Critical Biorchestra Co Ltd
Publication of AU2021260191A1 publication Critical patent/AU2021260191A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844—Nucleic acid amplification reactions
    • C12Q1/686—Polymerase chain reaction [PCR]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2537/00—Reactions characterised by the reaction format or use of a specific feature
    • C12Q2537/10—Reactions characterised by the reaction format or use of a specific feature the purpose or use of
    • C12Q2537/165—Mathematical modelling, e.g. logarithm, ratio
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pathology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AU2021260191A 2020-04-23 2021-04-23 Diagnostic methods using miR-485-3p expression Abandoned AU2021260191A1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202063014633P 2020-04-23 2020-04-23
US63/014,633 2020-04-23
US202063047206P 2020-07-01 2020-07-01
US63/047,206 2020-07-01
US202063064305P 2020-08-11 2020-08-11
US63/064,305 2020-08-11
PCT/IB2021/053353 WO2021214720A1 (en) 2020-04-23 2021-04-23 Diagnostic methods using mir-485-3p expression

Publications (1)

Publication Number Publication Date
AU2021260191A1 true AU2021260191A1 (en) 2022-11-17

Family

ID=78270846

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2021260191A Abandoned AU2021260191A1 (en) 2020-04-23 2021-04-23 Diagnostic methods using miR-485-3p expression

Country Status (8)

Country Link
US (1) US20230167502A1 (https=)
EP (1) EP4139488A4 (https=)
JP (1) JP2023522402A (https=)
KR (1) KR20230014705A (https=)
CN (1) CN115917008A (https=)
AU (1) AU2021260191A1 (https=)
CA (1) CA3175419A1 (https=)
WO (1) WO2021214720A1 (https=)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090156459A1 (en) * 2007-11-16 2009-06-18 Pharmain Corporation Cationic-Core Carrier Compositions for Delivery of Therapeutic Agents, Methods of Making and Using the Same
RU2626540C2 (ru) * 2011-04-18 2017-07-28 Диамир, Ллс Способы обнаружения патологических изменений в органе или системе органов
US9951330B2 (en) * 2013-07-11 2018-04-24 The Trustees Of Columbia University In The City Of New York Micrornas that silence tau expression
CN105917005B (zh) * 2013-11-18 2020-09-11 迪阿米尔有限责任公司 使用来自体液的miRNA检测和监控帕金森病(PD)的方法
WO2018139759A1 (ko) * 2017-01-26 2018-08-02 주식회사 바이오오케스트라 마이크로 rna를 이용한 알츠하이머병 진단방법
WO2018139819A1 (ko) * 2017-01-26 2018-08-02 주식회사 바이오오케스트라 마이크로 rna를 이용한 뇌 질환 예방 또는 치료 용도
KR102105016B1 (ko) * 2019-12-12 2020-04-28 주식회사 바이오오케스트라 miR-485-3p를 이용한 알츠하이머병 진단 방법

Also Published As

Publication number Publication date
WO2021214720A1 (en) 2021-10-28
EP4139488A4 (en) 2024-05-22
EP4139488A1 (en) 2023-03-01
US20230167502A1 (en) 2023-06-01
CN115917008A (zh) 2023-04-04
CA3175419A1 (en) 2021-10-28
JP2023522402A (ja) 2023-05-30
KR20230014705A (ko) 2023-01-30

Similar Documents

Publication Publication Date Title
US20230256119A1 (en) Compositions and methods for preparing an alzheimer's disease animal model using microrna
US20230304014A1 (en) Mirna-485 inhibitor for huntington's disease
US20230126157A1 (en) Mirna-485 inhibitor for gene upregulation
US20230167502A1 (en) Diagnostic methods using mir-485-3p expression
WO2021156833A1 (en) Use of mirna-485 inhibitors for treating tauopathy
US20220081690A1 (en) Use of mir-204 inhibitor to increase nurr1 protein expression
US20230167447A1 (en) Compositions for FNIP1/FNIP2 Gene Modulation and Methods Thereof
WO2022264038A1 (en) Use of mirna-485 inhibitors for treating inflammasome-related diseases or disorders
US20230119699A1 (en) Diagnostic methods using sirt1 expression
US20230121720A1 (en) Diagnostic methods using pcg-1a expression
WO2022003609A1 (en) Snp diagnostic methods
US20240294908A1 (en) Use of mirna-485 inhibitors for treating diseases or disorders associated with abnormal nlrp3 expression
US20240117350A1 (en) Use of mirna-485 inhibitor to regulate psd95, synaptophysin, and caspase-3 expression
WO2024127317A1 (en) Treating mitochondrial dysfunction with mirna-485 inhibitor
WO2023089506A1 (en) Amplification-free methods for measuring mirna
EP4634381A1 (en) Compositions and methods for treating neurological diseases

Legal Events

Date Code Title Description
MK1 Application lapsed section 142(2)(a) - no request for examination in relevant period